慢性丙型肝炎合并2型糖尿病患者临床特征及胰岛素抵抗对抗病毒疗效影响的Meta分析

doi:10.3969/j.issn.1672-5069.2016.04.013

摘要/Abstract

摘要： 目的分析慢性丙型肝炎（CHC）合并2型糖尿病患者的临床特征及胰岛素抵抗（IR）对干扰素治疗CHC患者临床疗效的影响。方法应用计算机检索PubMed、Ovid、ScienceDirect、Embase、万方、维普数据库1970年至2015年1月发表的关于CHC合并2型糖尿病的临床特征及IR与CHC抗病毒治疗效果关系的文献。应用RevMan 5.2 软件进行Meta分析。结果本研究纳入22篇合格文献,全部为英文文献。关于CHC合并2型糖尿病临床特征文献11篇,IR对干扰素治疗CHC病毒学应答产生影响文献11篇;CHC合并2型糖尿病患者的年龄、体质指数（BMI）显著高于单纯CHC或单纯糖尿病患者[P=0.0001,SMD=0.30,95%CI（0.15,0.45）,P=0.04,SMD= 0.17,95%CI（0.01,0.34）],CHC合并2型糖尿病患者糖尿病家族史显著多于单纯CHC或单纯糖尿病患者[P=0.01,RR=1.07,95% CI（1.02,1.13）];CHC合并2型糖尿病患者感染HCV基因1型的比例显著低于单纯CHC患者[P=0.01,RR=0.82,95%CI（0.71,0.95）],但两组感染2型或3型比例无显著性差异[P=0.25,RR=1.16,95%CI（0.90,1.50）,P=0.92,RR=1.06,95%CI（0.30,3.78）]）;干扰素治疗CHC患者获得非持续病毒学应答（NSVR）组HOMA-IR水平和IR发生率显著高于获得持续病毒学应答（SVR）组[P<0.0001,SMD=0.80,95%CI （0.63,0.97）,P<0.0001,OR=2.0,95%CI（1.59,2.52）]。结论 CHC合并2型糖尿病患者临床特征为高龄、高BMI水平和多伴有糖尿病家族史。感染基因1型CHC患者合并2型糖尿病机会小,而合并IR会降低干扰素抗病毒治疗后SVR发生率,是影响干扰素治疗CHC疗效的重要不利因素之一。

关键词: 慢性丙型肝炎, 2型糖尿病, 胰岛素抵抗, 基因型, 干扰素-α

Abstract: Objective To investigate the clinical characteristics of patients with chronic hepatitis C（CHC） with concomitant type 2 diabetes and to assess the impact of insulin resistance（IR） on sustained virological response （SVR） in patients with hepatitis C to treatment of interferon-α（IFN-α）. Methods A systematic search of electronic databases for randomized clinical trials in Pubmed,Ovid,Science Direct,Embase,Wanfang database and VIP database from 1970 to January,2015 was done as respect to clinical features of CHC with type 2 diabetes,and the correlation between IR and SVR. The Meta analysis was performed by using the RevMan 5.2 software. Result Twenty-two papers published in English were retrieved in this study,with eleven on CHC with type two diabetes,and eleven on IR impacting response to IFN-α therapy. Patients with CHC and type 2 diabetes had older age and higher BMI than in patients with CHC or diabetes alone [P=0.0001,SMD=0.30,95%CI （0.15,0.45）,P=0.04,SMD=0.17,95%CI（0.01,0.34）];More patients with CHC and type 2 diabetes had family history of diabetis than in patients with CHC or diabetes alone[P=0.01,RR=1.07,95%CI（1.02,1.13）];The incidence of genotype 1 infection in CHC patients with type 2 diabetes was significantly lower than in that of CHC alone[P=0.01,RR=0.82,95%CI（0.71,0.95）],while there was no significant differences as respect of genotypes 2/3 infection in the two groups[P=0.25,RR=1.16,95%CI（0.90,1.50）,P=0.92,RR=1.06,95%CI （0.30,3.78）];The incidence of IR was higher in CHC patients with non-sustained virological response（NSVR） to interferon-α therapy than in those who got SVR [P<0.0001,SMD=0.80,95%CI（0.63,0.97）,P<0.0001,OR=2.0,95%CI （1.59,2.52）]. Conclusion s Patients with CHC and type 2 diabetes tends to be elderly with higher BMI levels and much more family history of diabetes. IR is associated with a lower SVR in CHC patients receiving IFN-α therapy.

Key words: Hepatitis C, Type 2 diabetes, Interferon-α, Genotypes, Insulin resistance

刘菲菲, 张海月, 张倩, 王鲁文, 龚作炯. 慢性丙型肝炎合并2型糖尿病患者临床特征及胰岛素抵抗对抗病毒疗效影响的Meta分析[J]. 实用肝脏病杂志, 2016, 19(4): 436-440.

Liu Feifei, Zhang Haiyue, Zhang Qian, et al. Clinical features of patients with chronic hepatitis C with concomitant diabetes type 2 and impact of insulin resistance on efficacy of antiviral therapy: a Meta analysis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 436-440.

参考文献

[1] Moucari R,Asselah T,Cazals-Hatem D,et al. Insulin resistance in chronic hepatitis C:association with genotypes 1 and 4,serum CHC RNA level,and liver fibrosis. Gastroenterology,2008,134（2）: 416-423.
[2] Naing C,Mak JW,Ahmed SI,et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol,2012,18（14）:1642-1651.
[3] Guo X,Jin M,Liu K, et al. Type 2 diabetes mellitus and the risk of hepatitis C virus infection:A systematic review. Sci Rep, 2013,3:2981.
[4] Zein NN,Abdulkarim AS,Wiesner RH,et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C,alcohol,or cholestatic disease. J Hepatol,2000,32（2）:209-217.
[5] Mason AL,Lau JYN,Hoang N,et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology,1999,29（2）:328-333.
[6] Papatheodoridis GV,Chrysanthos N,Savvas S,et al. Diabetes mellitus in chronic hepatitis B and C:prevalence and potential association with the extent of liver fibrosis. J Viral Hepat,2006,13（5）:303-310.
[7] Chehadeh W,Abdella N,Ben-Nakhi A,et al. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol,2009,24（1）: 42-48.
[8] Antonelli A,Ferri N,Fallahi P,et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care,2005,28（10）:2548-2550.
[9] Chen HF,Li CY,Chen P,et al. Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc,2006,69（4）:146-152.
[10] Howard AA,Klein RS,Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis,2003,36（10）:1318-1323.
[11] Huang JF,Dai CY,Hwang SJ,et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area:an epidemiological link with virological implication. Am J Gastroenterol,2007,102（6）:1237-1243.
[12] Jadoon NA,Shahzad MA,Yaqoob R,et al. Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association. Virol J,2010,7:304.
[13] Rouabhia S,Malek R,Bounecer H,et al. Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol,2010,16（27）:3427-3431.
[14] Lecube A,Hernandez C,Genesca J,et al. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care,2004,27（11）: 2669-2675.
[15] Romero-Gómez M,Vilria MDM,Andrade RJ,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 2005, 128（3）:636-641.
[16] Poustchi H,Negro F,Hui J,et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol,2008,48（1）:28-34.
[17] Chu CJ,Lee SD,Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther,2009,29（1）:46-54.
[18] Dai CY,Huang JF,Hsieh MY,et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol,2009,50（4）:712-718.
[19] Fattovich G,Covolo L,Pasino M,et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int,2011,31（1）:66-74.
[20] Bortoletto G,Scribano L,Realdon S,et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat,2010,17（7）:475-480.
[21] Akuta N,Suzuki F,Hirakawa M,et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of CHC RNA by antiviral therapy. J Med Virol,2011,83（6）:1016-1022.
[22] Conjeevaram HS,Kleiner DE,Everhart JE,et al. Race,insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology,2007,45（1）:80-87.
[23] Grasso A,Malfatti F,Leo PD, et al. Insulin resistance predicts rapid virological response in non-diabetic,non-cirrhotic genotype 1 CHC patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol,2009,51（6）:984-990.
[24] Miyaaki H,Ichikawa T,Nakao K,et al. Predictive value of suppressor of cytokine signal 3（SOCS3） in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res,2009,39（9）:850-855.
[25] Mizuta T,Kawaguchi Y,Eguchi Y,et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci, 2010,55（1）:183-189.
[26] Lavanchy D. The global burden of hepatitis C. Liver Int, 2009,29 （Suppl 1）:74-81.
[27] Kissebah AH,Peiris AN. Biology of regional body fat distribution:relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev,1989,5（2）:83-109.
[28] Bahtiyar G,Shin JJ,Sower JR,et al. Association of diabetes and hepatitis C infection:epidemiologic evidence and pathophysiologic insights. Curr Diab Rep,2004,4（3）:194-198.
[29] Shintani Y,Fujie H,Miyoshi H,et al. Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology,2004,126（3）:840-848.